• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconOzempic

Ozempic

Page 2 of 9
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
Health
Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars
By Ryan HoggMay 9, 2025
Novo Nordisk slides on pressure from Lilly’s pill study
Retail
Novo Nordisk slides on pressure from Lilly’s pill study
By Marthe Fourcade and BloombergApril 22, 2025
Ozempic and Wegovy pumped $26 billion into Novo Nordisk last year. Can the pharma giant find its next breakthrough before the boom ends?
Magazine
Ozempic and Wegovy pumped $26 billion into Novo Nordisk last year. Can the pharma giant find its next breakthrough before the boom ends?
By Vivienne WaltMarch 31, 2025
Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
Finance
Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
By Chris MorrisMarch 7, 2025
Interest in GLP-1 medications like Ozempic will continue to grow given the multiple health conditions they can improve.
Commentary
The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up
By Wendy BarnesMarch 4, 2025
Close up of a man's face
Health
50-year-old security guard lost 70 pounds on Wegovy—then gained two pants sizes when he lost insurance coverage
By Tom Murphy and The Associated PressFebruary 24, 2025
Semaglutide medications Wegovy and Ozempic are pictured
Health
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
By Bloomberg, Madison Muller, Ike Swetlitz and Naomi KresgeFebruary 21, 2025
A woman injects herself with medication.
Health
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
By Lindsey LeakeFebruary 11, 2025
Novo Nordisk President and CEO Lars Fruergaard Jorgensen testifies before the Senate Health, Education, Labor, and Pensions Committee in the Dirksen Senate Office Building on Capitol Hill on September 24, 2024 in Washington, DC. The committee heard testimony from Jorgensen about the price of popular pharmaceuticals made by Novo Nordisk that help treat diabetes and obesity, including Wegovy and Ozempic.
Leadership
As U.S. firms scrap diversity targets, the CEO behind Ozempic and Wegovy took a pay cut for missing them
By Ryan HoggFebruary 5, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
Health
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
By Ryan HoggFebruary 5, 2025
A person stands on a scale.
Health
Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
By Lindsey LeakeFebruary 3, 2025
Ozempic and Wegovy medications side by side
Health
Ozempic and Wegovy surge to national approval with most U.S. adults considering it ‘a good thing’ to treat obesity
By The Associated Press, Kenya Hunter and Linley SandersJanuary 31, 2025
DeepSeek and Ozempic are complicating decarbonization forecasts
Environment
DeepSeek and Ozempic are complicating decarbonization forecasts
By Aaron Clark and BloombergJanuary 31, 2025
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Health
Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next
By Lindsey LeakeJanuary 29, 2025
A person, with only the midsection visible, injects Wegovy under the skin of their stomach.
Finance
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
By Greg McKennaJanuary 24, 2025
1
  • 1
  • 2
  • 3
  • 4
  • 5
...9
Most Popular
Personal Finance
After 40 investors rejected Jeff Bezos’ Amazon pitch, his parents offered $245,573 of their retirement savingsplaceholder alt text
By Marco Quiroz-GutierrezSeptember 22, 2026
Middle East
China suffers another setback in effort to de-dollarize global finance as anchor in the greenback's dominance quietly exits Beijing's payment schemeplaceholder alt text
By Jason MaSeptember 21, 2026
Economy
D.C.'s affordability headache has a silver bullet, new study shows: Tackling $40 trillion national debt would boost household income by $36,000placeholder alt text
By Eleanor PringleSeptember 23, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.